Clinical Data Pepaxti study supports use in wider myeloma population PharmaTimesPhase 2 bridge data show consistent outcomes in patients with impaired kidney functionOncologyRead full story pharminent May 20, 2026 (Last updated: May 21, 2026) PharmaTimes Phase 2 bridge data show consistent outcomes in patients with impaired kidney function Oncology Read full story Post navigation Previous: Beam one-ups Wave as both show promise of genetic editing for AATDNext: Pazdur declines to announce candidacy for vacated FDA commissioner role Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026